Product information

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Marketed

Current status date:

2015-03-18

Original market date: ^{See footnote 1}

2015-03-18

Product name:

GARDASIL 9

Description:

0.5ML SINGLE-DOSE VIALS AND PREFILLED SYRINGES

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02437058

Product Monograph/Veterinary Labelling:

Date: 2025-01-02 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

MERCK CANADA INC
16750 Route Transcanadienne
Kirkland
Quebec
Canada H9H 4M7

Class:

Human

Dosage form(s):

Suspension

Route(s) of administration:

Intramuscular

Number of active ingredient(s):

Schedule(s):

Schedule D

American Hospital Formulary Service (AHFS): ^{See footnote 3}

80:12.00

Anatomical Therapeutic Chemical (ATC): ^{See footnote 4}

J07BM03 PAPILLOMAVIRUS (HUMAN TYPES 6,11,16,18,31,33,45,52,58)

Active ingredient group (AIG) number:^{See footnote5}

0956550001

List of active ingredient(s)
Active ingredient(s) ^{See footnote8}	Strength
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN	40 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN	60 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN	40 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 31 L1 PROTEIN	20 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 33 L1 PROTEIN	20 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 45 L1 PROTEIN	20 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN	20 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 58 L1 PROTEIN	20 MCG / 0.5 ML
RECOMBINANT HUMAN PAPILLOMAVIRUS TYPE 6 L1 PROTEIN	30 MCG / 0.5 ML

Risk Management Plans ^{See footnote 7}

A Risk Management Plan (RMP) for this product was submitted.

Pharmacovigilance/Monitoring Activity
Clinical Trials

New search

Same active ingredient group number

Footnotes

Footnote 1

The earliest marketed date recorded in the Drug Product Database.

Return to footnote 1referrer

Footnote 3

The American Hospital Formulary Service permits an easy review of information on a group of drugs with similar activities and uses and allows the reader to determine quickly the similarities and differences among drugs within a group. AHFS® Pharmacologic/Therapeutic Classification© used with permission. © 2022, the American Society of Health-System Pharmacists, Inc. (ASHP). The Data is a part of the AHFS Drug Information®; ASHP is not responsible for the accuracy of transpositions from the original context.

Return to footnote 3referrer

Footnote 4

The purpose of the World Health Organization (WHO) Anatomical Therapeutic Chemical (ATC) classification system is to be used as a tool for drug utilization research in order to improve quality of drug use. Drugs are divided into different groups according to the organ or system on which they act and their chemical, pharmacological and therapeutical properties.

Return to footnote 4referrer

Footnote 5

The AIG number is a 10 digit number that identifies products that have the same active ingredient(s) and ingredient strength(s). The AIG is comprised of three portions:

the first portion (2 digits) identifies the number of active ingredients,
the second portion (5 digits) identifies the unique groups of active ingredients(s),
the last portion (3 digits) identifies the active ingredient group strength. The strength group has a tolerance of ‑2% to +10%.

Return to footnote 5referrer

Footnote 7

Refer to the Health Canada Guidance Documents - "Submission of Risk Management Plans and Follow-up Commitments" as well as "Submission of targeted Risk Management Plans Follow-up Commitments for Prescription Opioid-containing Products" for additional details.

Return to footnote 7referrer

Footnote 8

An asterisk * preceding an active ingredient indicates that the name of the active ingredient has been shortened to fit inside the database's field and that the active ingredient's full name is available on the product's Product Monograph/Veterinary Labelling available above and/or in the NOTES section of the QRYM_ACTIVE_INGREDIENTS extract available in the Drug product database (DPD) data extracts. The following link provides an explanation of the ordering of the data values contained in the DPD data extracts Read me file.

Return to footnote 8referrer

Application information

Related information

Contact us

Version 4.0.3

Report a problem or mistake on this page

"Page details"

Date modified:: 2019-03-01